Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer

References

• Papers of special note have been highlighted as:
   Google Scholar
• * of interest
   Google Scholar
• ** of considerable interest
   Google Scholar

• Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 1998;83(12):2638–2648. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9874472.
   PubMed Web of Science ®Google Scholar
• Massicotte M-H, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014;170(4):575–582. DOI:10.1530/EJE-13-0825.
   PubMed Web of Science ®Google Scholar
• Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612. DOI:10.1089/thy.2008.0403.
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Baudin E, Travagli J-P, et al. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299–310. DOI:10.1111/j.1365-2265.2004.02037.x.
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(12): 1671–1680.
   PubMed Web of Science ®Google Scholar
• Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–2142. DOI:10.1002/cncr.22244.
   PubMed Web of Science ®Google Scholar
• Wong KK, Laird AM, Moubayed A, et al. How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals. Nucl Med Commun. 2012;33(7):679–688. DOI:10.1097/MNM.0b013e3283529bf7.
   PubMed Web of Science ®Google Scholar
• Marzola MC, Pelizzo MR, Ferdeghini M, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36(4):414–421. DOI:10.1016/j.ejso.2010.01.001.
   PubMed Web of Science ®Google Scholar
• Jarzab B, Szpak-Ulczok S, Wloch J, et al. Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of Ct serum level. Thyroid Res. 2013;6(Suppl 1):S9. DOI:10.1186/1756-6614-6-S1-S9.
   Google Scholar
• Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(12):1671–1680. quiz 1680. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25505208.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Bastholt L, Dralle H, et al. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1(1):5–14. DOI:10.1159/000336977.
   PubMedGoogle Scholar
• Ravaud A, de la Fouchardière C, Asselineau J, et al. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist. 2010;15(2):212–213. author reply 214. DOI:10.1634/theoncologist.2009-0303.
   PubMed Web of Science ®Google Scholar
• Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–5268. DOI:10.1158/1078-0432.CCR-10-0994.
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab. 2014;99(5):1687–1693. DOI:10.1210/jc.2013-3713.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–4713. DOI:10.1200/JCO.2007.15.9566.
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27(23):3794–3801. DOI:10.1200/JCO.2008.18.7815.
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14):2323–2330. DOI:10.1200/JCO.2009.25.0068.
   PubMed Web of Science ®Google Scholar
• Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res. 2013;19(15):4239–4248. DOI:10.1158/1078-0432.CCR-13-0071.
   PubMed Web of Science ®Google Scholar
• Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767–772. DOI:10.1200/JCO.2009.23.6604.
   PubMed Web of Science ®Google Scholar
• Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2664–2671. DOI:10.1210/jc.2009-2461.
   PubMed Web of Science ®Google Scholar
• Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–141. DOI:10.1200/JCO.2011.35.5040.
   PubMed Web of Science ®Google Scholar

*The results of ZETA trial.

• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646. DOI:10.1200/JCO.2012.48.4659.
   PubMed Web of Science ®Google Scholar

**The results of EXAM study.

• Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol. 1999;17(1):380–393.
   PubMed Web of Science ®Google Scholar
• Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14(3):173–186. DOI:10.1038/nrc3680.
   PubMed Web of Science ®Google Scholar
• Eng C, Mulligan LM, Smith DP, et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer. 1995;12(3):209–212.
   PubMed Web of Science ®Google Scholar
• Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93(3):682–687. DOI:10.1016/S1077-9108(08)79021-2.
   PubMed Web of Science ®Google Scholar
• Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer. 2009;100(11):1777–1783.
   PubMed Web of Science ®Google Scholar
• Gimm O, Neuberg DS, Marsh DJ, et al. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene. 1999;18(6):1369–1373. DOI:10.1038/sj.onc.1202418.
   PubMed Web of Science ®Google Scholar
• Dvorakova S, Vaclavikova E, Sykorova V, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol. 2008;284(1–2):21–27. DOI:10.1016/j.mce.2007.12.016.
   PubMed Web of Science ®Google Scholar
• Giunti S, Antonelli A, Amorosi A, et al. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol. 2013;2013:803171. DOI:10.1155/2013/803171.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Antona C, Muñoz-Repeto I, Inglada-Pérez L, et al. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma. Endocr Relat Cancer. 2013;20(4):611–619. DOI:10.1530/ERC-12-0316.
   PubMed Web of Science ®Google Scholar
• Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 1997;82(11):3741–3747. DOI:10.1210/jcem.82.11.4340.
   PubMed Web of Science ®Google Scholar
• Bentzien F, Zuzow M, Heald N, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid. 2013;23(12):1569–1577. DOI:10.1089/thy.2013.0137.
   PubMed Web of Science ®Google Scholar

*A mechanism of action of cabozantinib.

• Zhang Y, Guessous F, Kofman A, et al. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs. 2010;13(2):112–121. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3268517&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308. DOI:10.1158/1535-7163.MCT-11-0264.
   PubMed Web of Science ®Google Scholar

*A mechanism of action of cabozantinib.

• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660–2666. DOI:10.1200/JCO.2010.32.4145.
   PubMed Web of Science ®Google Scholar

**First clinical experience in medullary thyroid carcinoma.

• Hoy SM. Cabozantinib: a review of its use in patients with medullary thyroid cancer. Drugs. 2014;74(12):1435–1444. DOI:10.1007/s40265-014-0265-x.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012–1023. DOI:10.1002/jcph.510.
   PubMed Web of Science ®Google Scholar
• Miles D, Jumbe NL, Lacy S, et al. Population pharmacokinetic model of cabozantinib in patients with medullary thyroid carcinoma and its application to an exposure-response analysis. Clin Pharmacokinet. 2015. DOI:10.1007/s40262-015-0295-x.
   PubMedGoogle Scholar
• Houvras Y, Wirth LJ. Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease. J Clin Oncol. 2011;29(19):2616–2618. DOI:10.1200/JCO.2010.34.0505.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Elisei R, Muller S, et al. Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients with documented RECIST progression at baseline. J Clin Oncol. 2015;33:6012.
   Web of Science ®Google Scholar

**Final overall survival analysis of EXAM study.

• Vaishampayan UN. Development of cabozantinib for the treatment of prostate cancer. Core Evid. 2014;9:61–67. DOI:10.2147/CE.S48498.
   PubMedGoogle Scholar
• Yavuz S, Apolo AB, Kummar S, et al. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. Thyroid. 2014;24(8):1223–1231. DOI:10.1089/thy.2013.0621.
   PubMed Web of Science ®Google Scholar
• Klein Hesselink EN, Steenvoorden D, Kapiteijn E, et al. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. 2015;172(5):R215–R225. DOI:10.1530/EJE-14-0788.
   PubMed Web of Science ®Google Scholar
• Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care. 2013;7(2):162–167. DOI:10.1097/SPC.0b013e32835ec861.
   PubMed Web of Science ®Google Scholar
• Krajewska J, Handkiewicz-Junak D, Jarzab B. Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opin Pharmacother. 2015;16(4):573–583. DOI:10.1517/14656566.2015.1005601.
   PubMed Web of Science ®Google Scholar
• Belum VR, Serna-Tamayo C, Wu S, et al. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol. 2015. DOI:10.1111/ced.12694.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Ciccolini K, Kloos RT, et al. Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. Thyroid. 2014;24(9):1329–1340. DOI:10.1089/thy.2013.0700.
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–1795. DOI:10.1038/sj.bjc.6603813.
   PubMed Web of Science ®Google Scholar

*Common side effects caused by vascular endothelial growth factor receptor inhibitors and its pathomechanisms.

• Liu S, Kurzrock R. Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014;40(7):883–891. DOI:10.1016/j.ctrv.2014.05.003.
   PubMed Web of Science ®Google Scholar
• Zhang Z-F, Wang T, Liu L-H, et al. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One. 2014;9(3):e90135. DOI:10.1371/journal.pone.0090135.
   Web of Science ®Google Scholar
• Qi W-X, Shen Z, Tang L-N, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol. 2014;78(4):748–762. DOI:10.1111/bcp.12387.
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta. 2006;1762(11–12):1109–1121. DOI:10.1016/j.bbadis.2006.04.005
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3–16. DOI:10.3109/08037051.2014.868629.
   PubMed Web of Science ®Google Scholar
• Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One. 2012;7(2):e30353. DOI:10.1371/journal.pone.0030353.
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 2015. DOI:10.1007/s40264-015-0300-1.
   Web of Science ®Google Scholar
• Scheffel RS, Dora JM, Siqueira DR, et al. Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis. Eur J Endocrinol. 2013;168(6):K51–K54. DOI:10.1530/EJE-13-0015.
   Web of Science ®Google Scholar
• Toubert M-E, Vercellino L, Faugeron I, et al. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid. 2011;21(4):451–454. DOI:10.1089/thy.2010.0270.
   PubMed Web of Science ®Google Scholar
• Schutz FAB, Je Y, Richards CJ, et al. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol. 2012;30(8):871–877. DOI:10.1200/JCO.2011.37.1195.
   PubMed Web of Science ®Google Scholar
• Qi W-X, Min D-L, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer. 2013;132(12):2967–2974. DOI:10.1002/ijc.27979.
   PubMed Web of Science ®Google Scholar
• Marino R, Orlandi F, Arecco F, et al. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J. 2014. DOI:10.1111/adj.12254.
   PubMed Web of Science ®Google Scholar
• Illouz F, Laboureau-Soares S, Dubois S, et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol. 2009;160(3):331–336. DOI:10.1530/EJE-08-0648.
   PubMed Web of Science ®Google Scholar
• Feldt S, Schüssel K, Quinzler R, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer. 2012;48(7):974–981. DOI:10.1016/j.ejca.2012.01.036.
   PubMed Web of Science ®Google Scholar
• Makita N, Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid. 2013;23(2):151–159. DOI:10.1089/thy.2012.0456.
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31–42. DOI:10.1056/NEJMoa075853.
   PubMed Web of Science ®Google Scholar
• De Groot JWB, Zonnenberg BA, van Ufford-Mannesse PQ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(9):3466–3469. DOI:10.1210/jc.2007-0649.
   PubMed Web of Science ®Google Scholar
• Illouz F, Braun D, Briet C, et al. Thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014. DOI:10.1530/EJE-14-0198.
   PubMed Web of Science ®Google Scholar
• Braun D, Kim TD, le Coutre P, et al. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab. 2012;97(1):E100–E105. DOI:10.1210/jc.2011-1837.
   PubMed Web of Science ®Google Scholar
• Blevins DP, Dadu R, Hu M, et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014;24(5):918–922. DOI:10.1089/thy.2012.0598.
   PubMed Web of Science ®Google Scholar